01
Overview
Peptides are not a single clinical category: approved peptide medicines and experimental peptides have very different evidence bases. Each molecule, route and indication must be evaluated individually.
All technology areas
03 / 06
SCIENTIFIC TECHNOLOGY LIBRARY / 03
Peptides & Molecular Platforms
Signalling pathways, molecular targets and investigational peptides.
Editorial review: November 202603 / 0602
Biological mechanism
Specific peptides can affect receptors, enzymes or signalling pathways. A plausible mechanism does not establish therapeutic benefit.
03
Preclinical evidence
Mechanistic studies use cellular and animal models and are sensitive to dose, pharmacokinetics and model selection.
04
Human studies
Some peptide-based medicines are established for specific indications, while numerous popular research peptides have little or inadequate human efficacy and safety data.
05
Limitations & safety
Purity, aggregation, immunogenicity, route of administration, manufacturing quality and applicable regulation matter. FDA has published safety concerns for certain substances.
References and further reading
This page is for scientific education, not personal medical advice, an approved-treatment claim or a product recommendation. Each source must be read within its own scope.
